CYduct Diagnostics, Inc.
CYDX · OTC
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 45.5% | -13% | 74.5% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 62.5% | 65.8% | 68.9% | 70.1% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $0 | $0 | $0 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -355.8% | -603.9% | -394.2% | -935.1% |
| Other Income/Exp. Net | -$0 | -$0 | -$0 | -$0 |
| Pre-Tax Income | -$0 | -$0 | -$0 | -$0 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -394.2% | -681.4% | -461.8% | -1,041.6% |
| EPS | -0.018 | -0.022 | -0.017 | -0.022 |
| % Growth | 15.7% | -28.6% | 22.6% | – |
| EPS Diluted | -0.018 | -0.022 | -0.017 | -0.022 |
| Weighted Avg Shares Out | 5 | 5 | 5 | 5 |
| Weighted Avg Shares Out Dil | 5 | 5 | 5 | 5 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -340.2% | -603.9% | -394.2% | -935.1% |